APIXABAN

✓ Medically ReviewedRxDirect Oral Anticoagulant (DOAC)⬛ BLACK BOX WARNINGAPPROVED
💡

Quick Summary

Apixaban is a highly selective, reversible, direct inhibitor of coagulation Factor Xa, administered orally as a non-vitamin K antagonist oral anticoagulant (NOAC). It is indicated for stroke prevention in non-valvular atrial fibrillation (NVAF) and for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Unlike warfarin, apixaban exhibits predictable pharmacokinetics that allow for fixed dosing without routine coagulation monitoring. However, its dependence on dual clearance pathways — cytochrome P450 3A4 (CYP3A4) metabolism and P-glycoprotein (P-gp) transport — necessitates careful dose adjustment in the elderly, those with renal impairment, and patients on strong dual inhibitors.

🔬

Drug Identity

GENERIC NAMEApixaban
MEDOBO IDMDBD0024
ATC CODEB01AF02
DRUG CLASSDirect Oral Anticoagulant (DOAC)
PHARMACOLOGICAL CLASSDirect Factor Xa Inhibitor
THERAPEUTIC CLASSAnticoagulant
THERAPEUTIC CATEGORYHaematology
CHEMICAL NAME1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
DRUG SOURCESynthetic
FDA APPROVAL2012
MODALITYSmall Molecule
DRUG TYPEstandard
MARKET STATUS● Approved
CORE USE TAGS
AnticoagulantFactor Xa InhibitorDOACAtrial FibrillationVTE
BRAND NAMES (GLOBAL)
EliquisApixaban TevaApixaban SandozApixaban AccordApixaban MylanApixaban ZentivaApixaban KrkaApixaban StadaApixaban HexalApixaban Viatriss
SYNONYMS
BMS-562247BMS-562247-01
📌

Indications & Uses

🎯 APPROVED INDICATIONS
  • To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
  • For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
  • For the treatment of DVT and PE.
  • To reduce the risk of recurrent DVT and PE following initial therapy.
🔬 OFF-LABEL USES
  • Left ventricular thrombus — increasingly used off-label as an alternative to warfarin, supported by observational data showing similar efficacy in thrombus resolution.
  • Treatment of portal vein thrombosis in cirrhotic patients without severe coagulopathy — supported by emerging observational cohorts.
  • Cerebral venous sinus thrombosis (CVST) — used off-label as an alternative to LMWH/warfarin after the acute parenteral phase, supported by the RESPECT-CVST trial and observational data.
  • Bioprosthetic valve thrombosis — investigated in the PROSPECT-XA and other trials, though routine use remains off-label pending larger RCTs.
MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current prescribing information, institutional protocols, and official clinical guidelines. Medobo is not responsible for clinical decisions made based on this content.